Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
What CK Life Sciences Int'l. (Holdings) (SEHK:775) investors are watching now
With no fresh headline event driving CK Life Sciences Int'l. (Holdings) (SEHK:775) today, the stock's recent performance and current profitability profile are front of mind for investors assessing how the business is positioned.
See our latest analysis for CK Life Sciences Int'l. (Holdings).
At a share price of HK$0.85, CK Life Sciences Int'l. (Holdings) has posted a 30 day share price return of 2.41% and a 1 year total shareholder return of 84.78%. This suggests that shorter term momentum is modest compared with the stronger longer term payoff for reinvested holders.
If this kind of move has you looking for other opportunities in the sector, it could be a good moment to scan healthcare stocks for more health related names to research next.
With HK$5,492.64m in revenue, a reported net loss of HK$278.39m and an intrinsic value estimate slightly above the current HK$0.85 share price, you now have to ask: is this a genuine opportunity, or is the market already baking in future growth?
Price-to-Sales of 1.5x: Is it justified?
On a P/S of 1.5x at a last close of HK$0.85, CK Life Sciences Int'l. (Holdings) screens as lowly priced compared with both direct peers and the wider Hong Kong biotechs group.
The P/S ratio compares a company's market value to its revenue, which can be useful for businesses that are currently loss making, as is the case here. For a health and biotech focused group with HK$5,492.64m in revenue and a reported net loss, revenue based yardsticks often receive more attention than earnings based ones.
Here, the gap to peers is large. CK Life Sciences Int'l. (Holdings) sits on a 1.5x P/S against a peer average of 26.2x, and the Hong Kong Biotechs industry average of 14.5x. That contrast indicates the market is assigning a much lower value to each dollar of sales than it does elsewhere in the sector.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-Sales of 1.5x (UNDERVALUED)
However, you also have to weigh the current net loss of HK$278.39m and the group's broad mix of businesses, which can complicate margins and execution.
Find out about the key risks to this CK Life Sciences Int'l. (Holdings) narrative.
Another view using our DCF model
There is a clear tension between the low 1.5x P/S and our DCF output. While the sales based view points to attractive pricing, the SWS DCF model suggests something very different, with an estimated fair value of HK$0.16 per share. On that framework, the stock appears overvalued.
That gap raises a simple question for you as an investor: which lens do you trust more, the market paying less than peers for each dollar of revenue, or a cash flow model that points to a much lower fair value?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day ( check out CK Life Sciences Int'l. (Holdings) for example ). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 865 undervalued stocks based on their cash flows . If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Build Your Own CK Life Sciences Int'l. (Holdings) Narrative
If you see the data differently or prefer to test your own assumptions, you can build a complete CK Life Sciences Int'l. (Holdings) view in just a few minutes: Do it your way .
A great starting point for your CK Life Sciences Int'l. (Holdings) research is our analysis highlighting 2 important warning signs that could impact your investment decision.
Looking for more investment ideas?
Do not stop with one company when you can quickly scan a wider field of opportunities that match your style, risk comfort and return expectations.
-
Spot potential value plays early by checking out these 865 undervalued stocks based on cash flows that are priced below what their cash flows suggest.
-
Tap into growth themes by reviewing these 24 AI penny stocks that are tied to advances in artificial intelligence.
-
Build a watchlist of income candidates using 3%","yLinkElement":"context_link","yModuleName":"content-canvas","yTrafficOrigin":"content-canvas default"}" rel="noopener noreferrer nofollow">these 12 dividend stocks with yields > 3% that currently offer yields above 3%.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include 0775.HK .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
